Cancer patients who are undergoing targeted therapy can look forward to a new blood test that could tell their doctors whether the treatment is working within one day after the start of the treatment. This will significantly speed up the evaluation process and enable doctors to adjust the treatment plan, if necessary, to improve patients’ chances of recovery.
Unlike conventional chemotherapies that interfere with all rapidly dividing cells and can cause widespread damage to cells, targeted medicines attack specific molecules that instruct cancer cells to grow and spread and, in turn, block the abnormal growth of cancer. Despite the precise nature of targeted drugs, current clinical evaluation of their treatment in solid tumors primarily relies on either tumor volumetric imaging, insensitive and delayed, or invasive tissue biopsies.
Assistant Professor Shao Huilin and her research team from the Department of Biomedical Engineering and Institute for Health Innovation & Technology (iHealthtech) at the National University of Singapore (NUS) have developed a technology that is accurate, less invasive, and significantly brings forward the evaluation window, by using liquid biopsies.
Success rate available in 24 hours after cancer treatment
The technique, termed extracellular vesicle monitoring of small-molecule chemical occupancy and protein expression (ExoSCOPE), is the first of its kind in the world. It takes advantage of extracellular vesicles (EVs) secreted by cancer cells and circulating in the blood as a reflective indicator of drug effectiveness in solid tumors.
“Conventional procedures such as tumor imaging are not only expensive but also delayed. For these methods, treatment effectiveness can only be determined after weeks. Using the ExoSCOPE, we can directly measure the outcomes of drug effectiveness within 24 hours of treatment initiation. This will significantly reduce the time and cost for cancer treatment monitoring,” said the lead scientist Asst Prof Shao.
She added, “This method requires only a tiny amount of blood sample for the analysis, and each test takes less than one hour to complete. So, it is less invasive and yet more informative. In this way, doctors could monitor a patient’s response to treatment more regularly during the course of the treatment, and make timely adjustments to customize the treatment for better outcomes.”
The research was first published in the scientific journal Nature Nanotechnology on 8 March 2021.
Sensitive measurement of drug interactions
To achieve sensitive and rapid analysis of drug efficacy through blood samples, the NUS research team developed the ExoSCOPE as an integrated nanotechnology platform. It measures EVs, which are membrane vesicles of dimension at least a hundred times smaller than the diameter of human hair and invisible under conventional light microscopy. When a targeted cancer drug attaches to a cancer cell during successful cancer treatment and interferes with tumor growth, the treated cell will release into the bloodstream EVs containing the drug.
The ExoSCOPE platform harnesses a complementary chemical biology approach and sensor development to measure these delicate drug changes in EVs.
“Current technologies to measure drug-target interactions require complex processing and invasive tissue biopsies, limiting their clinical utility for cancer treatment monitoring. By using specially designed chemical probes, our platform is susceptible in capturing and labeling EVs in a small blood sample to assess drug-target interactions,” said Dr. Sijun Pan, Research Fellow from NUS iHealthtech, and co-first author of the study.
“The ExoSCOPE sensor contains millions of gold nanorings to capture the EVs and amplify their drug labeling signals to induce strong light signals. These light signals are then processed to give a readout to indicate drug effectiveness,” said Mr. Zhang Yan, a doctoral student from NUS Department of Biomedical Engineering and iHealthtech, and co-first author of the study.
Using the developed ExoSCOPE platform, the team collected information on different types of EVs and their drug changes when treated with various targeted therapies. The platform identifies cancer-released EVs and monitors their drug dynamics over time to accurately distinguish treatment sensitivity and resistance.
“Existing blood pharmacokinetic or pharmacodynamic approaches measure the total drug concentration in blood. This ensemble information does not reflect drug efficacy in tumors. The ExoSCOPE, however, measures drug changes in cancer-released EVs to reflect tumor treatment responses accurately,” explained Asst Prof Shao.
Encouraging results from clinical study
In a clinical trial involving 163 blood samples from 106 patients, the ExoSCOPE has shown encouraging results on lung cancer patients to enable timely evaluation of patients’ targeted treatment outcomes. Compared against the gold standard of volumetric tumor imaging, which was performed at the end of the entire treatment regimen, the ExoSCOPE achieved an accuracy rate of 95 percent, but within 24 hours of treatment initiation.
This technique’s superior analytical performance paves the way for blood-borne EVs to monitor different interactions between drugs and protein targets in the human body.
“The ExoSCOPE presents a paradigm shift in blood-based drug evaluation for targeted drug selection and real-time treatment monitoring,” said Asst Prof Shao. “The technique can also empower the clinical community to make more timely treatment decisions.”
Next steps
The nine-member NUS team took two years (from 2019 to 2021) to develop and validate the ExoSCOPE platform. Their next challenge is to expand the platform to measure the efficacy of different drugs and apply the technology to a spectrum of diseases from cancers to cardiovascular and neurological disease. A patent has been filed for ExoSCOPE, and the NUS team hopes to bring this technology to market in the next three years.
“I hope our technology can contribute towards personalized treatment, to guide the selection, dosage, and duration of different treatments, and improve treatment outcomes,” said Asst Prof Shao.
Journal Reference:
- Pan, S., Zhang, Y., Natalia, A. et al. Extracellular vesicle drug occupancy enables real-time monitoring of targeted cancer therapy. Nat. Nanotechnol. (2021). DOI: 10.1038/s41565-021-00872-w